What is AllCells?
AllCells is a specialized entity dedicated to supplying high-quality human primary cells and whole tissue products essential for medical, scientific, and academic research. Their comprehensive catalog features cryopreserved and fresh cells, including leukopaks, bone marrow, and cord blood, meticulously prepared to serve global life science researchers and bio-manufacturing organizations. The company distinguishes itself through robust donor management protocols and custom cell isolation services, ensuring both prompt delivery and adherence to Good Manufacturing Practice (GMP) guidelines. AllCells plays a crucial role in advancing the development of complex therapies, particularly within the burgeoning cell and gene therapy sector.
How much funding has AllCells raised?
AllCells has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
What's next for AllCells?
The substantial enterprise-level capital infusion positions AllCells for accelerated expansion and enhanced service offerings. This strategic investment is anticipated to fuel advancements in their research and development capabilities, potentially broadening their product portfolio and deepening their market penetration within the life sciences and bio-manufacturing industries. The company's focus on critical cell and gene therapy research suggests a future trajectory geared towards supporting innovative therapeutic breakthroughs and scaling their operations to meet increasing global demand for specialized biological materials.
See full AllCells company page
